Which fetal abnormalities can cause intra‑uterine growth restriction (IUGR) and what are the recommended diagnostic and management approaches?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fetal Abnormalities Causing IUGR

Chromosomal disorders and congenital malformations are responsible for approximately 20% of all fetal growth restriction cases, making them the second most common cause after placental insufficiency. 1

Major Fetal Abnormality Categories

Chromosomal Abnormalities

  • Chromosomal disorders account for approximately 6.4% of early-onset FGR cases, even without structural malformations. 2
  • Autosomal trisomies are the most common chromosomal causes, including:
    • Trisomy 21 (Down syndrome) 3
    • Trisomy 18 (Edwards syndrome) 3
    • Trisomy 13 (Patau syndrome) 3
  • Sex chromosome abnormalities such as Turner syndrome (45,X) and 47,XYY also cause IUGR 3
  • Triploidy and other rare trisomies (trisomy 7, trisomy 16) have been documented 3
  • Structural chromosomal abnormalities including translocations and deletions can result in growth restriction 3

Congenital Malformations

  • Approximately 10% of fetuses with FGR have congenital anomalies 4
  • Structural malformations contribute to the 20% of FGR cases attributed to fetal abnormalities 1
  • A detailed fetal structural survey is essential as part of the diagnostic workup 4

Genetic Syndromes

  • Genetic syndromes are more common etiologies earlier in gestation 4
  • These conditions often present with symmetrical growth restriction 5

Intrauterine Infections

  • Viral infections, particularly cytomegalovirus (CMV), are important fetal causes of IUGR 4, 6
  • CMV is the primary infectious etiology to evaluate in early-onset FGR 2
  • Infections are more commonly identified as causative factors in early-onset cases 4

Diagnostic Approach

Timing-Based Evaluation Strategy

For early-onset FGR (diagnosed <32 weeks):

  • Offer prenatal diagnostic testing with chromosomal microarray analysis (CMA), which provides a 4-10% incremental diagnostic yield over standard karyotyping 2
  • Perform detailed obstetrical ultrasound examination to identify structural abnormalities 2
  • Consider PCR for CMV in women with unexplained FGR who elect diagnostic testing with amniocentesis 1, 2
  • Do NOT screen for toxoplasmosis, rubella, or herpes in the absence of other risk factors 1

For late-onset FGR:

  • Placental insufficiency predominates as the cause, especially related to hypertension and maternal vascular disease 4
  • Chromosomal anomalies and infections are less likely but should still be considered if other features are present 4

Specific Testing Recommendations

  • Chromosomal microarray analysis is recommended when unexplained isolated FGR is diagnosed at <32 weeks of gestation (GRADE 1C) 1
  • CMA should also be offered when FGR is detected with fetal malformation, polyhydramnios, or both 2
  • Doppler studies of maternal and fetal circulations are the most effective method to differentiate IUGR fetuses secondary to placental dysfunction from those secondary to aneuploidy, genetic syndromes, and intrauterine infections 5

Management Implications

Surveillance Adjustments

  • Once fetal growth restriction is diagnosed, serial umbilical artery Doppler assessment should be performed to assess for deterioration 1
  • The presence of chromosomal abnormalities or congenital malformations may alter the intensity and type of monitoring required 5
  • Exclusion of structural and/or chromosomal anomalies helps guide appropriate counseling regarding prognosis 5

Common Pitfalls

  • Failing to offer genetic testing for early-onset FGR (<32 weeks) misses the 6.4% of cases with chromosomal abnormalities even without visible structural defects 2
  • Ordering unnecessary infectious disease screening (toxoplasmosis, rubella, herpes) without specific risk factors wastes resources and delays appropriate management 1
  • Assuming all IUGR is placental in origin without performing a detailed anatomic survey misses the 10% with congenital anomalies 4
  • Using standard karyotyping alone instead of CMA loses the 4-10% incremental diagnostic yield in detecting submicroscopic abnormalities 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Early-Onset Fetal Growth Restriction: Causes and Evaluation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Asymmetric Intrauterine Growth Restriction Causes and Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Non-placental causes of intrauterine growth restriction.

Seminars in perinatology, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.